Related Experiment Video
Updated: Jul 15, 2026
12:36
Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
Pharmacogenomics and its implications for autoimmune disease
Colin J D Ross1, Hagit Katzov, Bruce Carleton
1Department of Medical Genetics, University of British Columbia (UBC), Centre for Molecular Medicine and Therapeutics, 950 West 28th Avenue, Vancouver, BC V5Z 4H4, Canada.
Journal of Autoimmunity
|April 10, 2007
Summary
Adverse drug reactions (ADRs) cause significant illness and death. Pharmacogenomics and the GATC project aim to identify genetic markers to predict and prevent ADRs in children.
Area of Science:
- Pharmacogenomics
- Genetics
- Pediatric Medicine
Background:
- Adverse drug reactions (ADRs) are a major cause of death and illness, with substantial economic costs.
- Genetic factors significantly influence drug response variability and the risk/severity of ADRs, accounting for 20-95% of this variability.
- Pharmacogenomics focuses on identifying genetic determinants of drug efficacy and ADRs, leading to clinical genetic tests for improved drug selection and dosing.
Purpose of the Study:
- To identify novel predictive genomic markers for severe adverse drug reactions (ADRs) in children.
- To establish a nationwide surveillance network for ADRs in Canadian pediatric hospitals.
- To collect DNA samples from children experiencing ADRs for genomic analysis.
Main Methods:
- Establishment of an adverse drug reaction (ADR) surveillance network across major Canadian children's hospitals.
- Collection of DNA samples from pediatric patients experiencing specific ADRs.
- Application of genomics-based technologies to identify genetic markers associated with ADRs.
Main Results:
- The GATC project established a nationwide ADR surveillance network in Canada.
- The project aims to identify novel genetic markers associated with severe ADRs in children.
- Genomic analysis will be applied to collected DNA samples to find ADR-associated genetic markers.
Conclusions:
- Pharmacogenomics offers a promising approach to mitigate the risks of adverse drug reactions.
- The GATC project is poised to identify critical genetic markers for ADR prediction in pediatric populations.
- Identifying these markers can lead to personalized medicine strategies, improving drug safety and efficacy in children.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...